Time to walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Fiche publication
Date publication
mars 2021
Journal
European journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, Wolinsky JS
Lien Pubmed
Résumé
Requiring a walking aid is a fundamental milestone in MS, represented by Expanded Disability Status Scale (EDSS) score ≥6.0. Here we assess the effect of ocrelizumab on time to EDSS≥6.0 in relapsing MS.
Mots clés
Multiple sclerosis, disease progression, interferon beta 1a, ocrelizumab, walking stick
Référence
Eur J Neurol. 2021 Mar 16;: